Health campaigners Just Treatment and Global Justice Now are threatening legal action against the UK government over a drug-pricing deal with the Trump administration. They accuse ministers of breaching parliamentary protocol and seek to revoke legislation that allows ministers to direct NHS spending on medicines.
Health campaigners Just Treatment and Global Justice Now are threatening legal action against the UK government over a drug-pricing deal with the Trump administration. They accuse ministers of breaching parliamentary protocol and seek to revoke legislation that raises the cost-effectiveness threshold for drugs on the NHS.
Campaigners are threatening legal action against the UK government over a drug pricing deal with Donald Trump, arguing a change to NHS drug approval processes is an "unlawful power grab" that undermines Nice's independence.
AstraZeneca will invest £300m in the UK, completing its Cambridge headquarters and building a digital research facility in Macclesfield. The announcement marks a U-turn after the pharma giant paused £650m in projects last year due to disillusionment with the NHS business environment. Prime Minister Keir Starmer hailed the investment as a 'major vote of confidence' in the UK economy.
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
Thirty-one MPs have launched a parliamentary challenge against new powers granted to Health Secretary Wes Streeting, allowing him to dictate NHS drug spending thresholds. Critics argue the move undermines the independence of Nice and favors US pharmaceutical interests.
China's volume-based procurement policy forces multinational drug companies to lower prices for public hospital purchases while allowing biotech firms to charge premium prices in the private market. The dual-track system benefits internet healthcare platforms and private healthcare providers like Alibaba Health, Yifeng and Hygeia, according to Citi research.
China's volume-based procurement policy, which mandates bulk drug purchases for public hospitals, is intensifying price competition for multinational pharmaceutical companies while creating more profitable channels for domestic biotech firms in the private market. Analysts note potential benefits for internet healthcare platforms, pharmacies, and private hospital services.
